Clinical Trials Logo

Uterine Cervical Dysplasia clinical trials

View clinical trials related to Uterine Cervical Dysplasia.

Filter by:

NCT ID: NCT06314113 Recruiting - Clinical trials for Low-Grade Intraepithelial Neoplasia of Cervix

Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection

EGCG-HPV
Start date: March 1, 2024
Phase:
Study type: Observational

The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.

NCT ID: NCT06273553 Not yet recruiting - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).

NCT ID: NCT06258564 Not yet recruiting - Recurrence Clinical Trials

The Adjuvant Effect of HPV Vaccination on Recurrence of Cervical Precancer or Carcinoma in Women Undergoing Conization

Start date: May 1, 2024
Phase:
Study type: Observational

Assessment of the association between human papillomavirus vaccination (HPV) and recurrences of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women undergoing conization.

NCT ID: NCT06243666 Not yet recruiting - Cervical Cancer Clinical Trials

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Start date: February 20, 2024
Phase:
Study type: Observational

The primary objective of this study is to evaluate the protective efficacy against future infections of HPV types 16/18 or related diseases and immuno-persistence (type specific IgG antibody) of the bivalent HPV vaccine in young female populations aged 9-17 years.

NCT ID: NCT06219018 Not yet recruiting - Clinical trials for High Risk Human Papillomavirus

Effect of Honey For CIN II

HoneyForCIN2
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase inthe normalization of CIN II lesions compared to expectant management.

NCT ID: NCT06191133 Not yet recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Start date: August 1, 2024
Phase: Phase 1
Study type: Interventional

Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia.

NCT ID: NCT06165614 Recruiting - Cervix Cancer Clinical Trials

Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

Start date: March 4, 2024
Phase: Phase 1
Study type: Interventional

To investigate the use of self-administered artesunate vaginal pessaries as treatment for cervical precancer in low and middle-income countries (LMIC). The central hypothesis of this study is that self-administered intravaginal Artesunate will be safe, and result in a clinical response among both HIV-positive and HIV-negative women with cervical precancer in LMICs.

NCT ID: NCT06149598 Recruiting - Cervical Cancer Clinical Trials

Coughing at Time of Cervical Biopsy

Start date: January 2, 2024
Phase: N/A
Study type: Interventional

To investigate the effect of coughing as an intervention to reduce pain in colposcopy guided biopsy.

NCT ID: NCT06137950 Recruiting - HPV Infection Clinical Trials

Interferon Alpha Therapy for Cervical CINI and HPV Infection

Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

Mongolia is a traditionally nomadic and population is scarce in rural areas. Thus, the medical care service is not sufficient. In 2000, Mongolian government has developed and implemented the millennium project in cooperation with WHO. During the years pap smear analysis of implemented in all rural areas and clinicians, lab technicians have been taught for the cervical cancer screening. However, the project has finished in 2015 and the rural and district hospitals has lost the trained professionals. Still the cervical cancer is in second place after liver cancer in women. The purpose of the study is to identify the type of HPV genotype and to treat the HPV infection by local interferon α2b. Materials and methods: HPV positive patients will be enrolled to the study. HPV genotype will be determined by the PCR in laboratory. Pap smear will be taken and staged by the CIN. Pathological tissue will be taken under colposcopy with acetic acid test. Follow up visit will be done on 10th, 30th days of the treatment. At the end of 90th days of treatment, pap and histology test will be repeated and CIN regression or viral eradication will be evaluated.

NCT ID: NCT06086054 Recruiting - Cervical Dysplasia Clinical Trials

Effect of a Childcare Resource on Cervical Cancer Prevention

Start date: October 31, 2023
Phase: N/A
Study type: Interventional

Aim 1: Determine the prevalence of unmet childcare needs among women with abnormal cervical cancer screening and establish the relevance of childcare as a social determinant of health in the context of cervical dysplasia. Aim 2: Conduct a pilot pragmatic patient-randomized control trial (RCT) to evaluate the effectiveness of an intervention linking eligible patients to our childcare facility compared to standard of care on retention in care, defined as show-rate for the initial visit in the gynecology dysplasia clinic. The intervention will consist of 1) patient navigation to our childcare facility prior to the initial visit in the gynecology dysplasia clinic and 2) placement of an electronic medical record (EMR) referral to our childcare facility. Hypothesis: The study team hypothesizes that women receiving the intervention will have increased retention in care compared to women randomized to standard of care among women with abnormal cervical cancer screening referred to gynecology for diagnostic work-up. These two aims will demonstrate the significance of childcare as a social determinant of health in the cervical cancer screening and diagnostic continuum by assessing the burden of unmet childcare needs among women with cervical dysplasia and measuring the effect of health system-integrated childcare as an intervention for unmet childcare needs on retention in care and subsequent completion of diagnostic work-up among women with cervical dysplasia. This study will rigorously provide the first evidence illustrating the effect of health systems' investment in addressing unmet childcare needs on preventive care like cervical cancer screening. The findings of this proposed pilot study will be utilized to develop future large-scale studies with extramural funding, building a longitudinal program of research on addressing childcare as a social determinant of health in this and other similar clinical contexts (e.g., breast cancer screening and treatment).